The prognostic value of proliferation indices: A study with in vivo bromodeoxyuridine and Ki-67

Breast Cancer Research and Treatment

Volumn 59, Issue 2, 2000, Pages 113-123

  Goodson III, William H ^a,c   Moore II, Dan H ^b   Ljung, Britt Marie ^a   Chew, Karen ^a   Mayall, Brian ^a   Smith, Helene S ^b   Waldman, Frederic M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NONE   (United States)

Author keywords

Breast cancer; Bromodeoxyuridine; Ki 67; Nodes; S phase; Survival

Indexed keywords

BROXURIDINE; KI 67 ANTIGEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LABELING INDEX; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; BROMODEOXYURIDINE; CELL CYCLE; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY, ADJUVANT; TUMOR MARKERS, BIOLOGICAL;

EID: 0034051625     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006344010050     Document Type: Article

References (44)

1. 1. Bloom HJG, Richardson WW: Histological grading and prognosis in breast cancer. Br J Cancer 11: 359-377, 1957
2. 2. Silvestrini R, Daidone MG, Di Fronzo G, Morabito A, Valagussa P, Bonadonna G: Prognostic implication of labeling index versus estrogen receptors and tumor size in node-negative breast cancer. Breast Cancer Res Treat 7: 161-169, 1986
3. 3. Silvestrini R, Daidone MG, Mastore M, Di Fronzo G, Coradini D, Boracchi P, Squicciarini P, Salvadori B, Veronesi U: Cell kinetics as a predictive factor in node-positive breast cancer treated with adjuvant hormone therapy. J Clin Onc 11: 1150-1155, 1993
4. 4. Meyer JS, Province M: Proliferative index of breast carcinoma by thymidine labeling: prognostic power independent of stage, estrogen and progesterone receptors. Breast Cancer Res Treat 12: 191-204, 1988
5. 5. Tubiana M, Pejovic MH, Koscielny S, Chavaudra N, Malaise E: Growth rate, kinetics of tumor cell proliferation and long-term outcome in human breast cancer. Int J Cancer 44: 17-22, 1989
6. 6. Toikkanen S, Joensuu H, Klemi P: The prognostic significance of nuclear DNA content in invasive breast cancer - a study with long-term follow-up. Br J Cancer 60: 693-700, 1989
7. 7. Ewers SB, Attewell R, Baldetorp B, Langstrom E, Killander D: Prognostic potential of flow cytometric S-phase and ploidy prospectively determined in primary breast carcinomas. Breast Cancer Res Treat 20: 93-108, 1992
8. 8. Ferno M, Baldetorp B, Borg A, Olsson H, Sigurdsson H, Killander D: Flow cytometric DNA index and S-phase fraction in breast cancer in relation to other prognostic variables and to clinical outcome. Acta Oncol 31: 157-165, 1992
9. 9. Gnant MF, Blijham G, Reiner A, Reiner G, Reynders M, Schutte B, van Asche C, Steger G, Jakesz R: DNA ploidy and other results of DNA flow cytometry as prognostic factors in operable breast cancer: 10-year results of a randomized study. Eur J Cancer 28: 711-716, 1992
10. 10. Camplejohn RS, Ash CM, Gillett CE, Raikundalia B, Barnes DM, Gregory WM, Richards MA, Millis RR: The prognostic significance of DNA flow cytometry in breast cancer: results from 881 patients treated in a single centre. Br J Cancer 71: 140-145, 1995
11. 11. Railo M, Nordling 5, Boguslawsky K, Leivonen M, Kyllonen L, von Smitten K: Prognostic value of Ki-67 immunolabeling in primary operable breast cancer. Br J Cancer 68: 579-583, 1993
12. 12. 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 16: 793-795, 1998
13. 13. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 14: 2843-2877, 1996
14. 14. Waldman FM, Chew K, Ljung BM, Goodson WH III, Hom J, Duarte LA, Smith HS, Mayall B: A comparison between bromodeoxyuridine and 3H thymidine labeling in human breast cancers. Modern Pathol 4: 718-722, 1991
15. 15. Goodson WH III, Ljung BM, Waldman F, Mayall B, Chew K, Moore DH II, Smith HS, Goldman ES, Benz C: In vivo measurement of breast cancer growth rate. Arch Surg 126: 1220-1223, 1991
16. 16. Goodson WH III, Ljung BM, Moore DH II, Mayall B, Waldman FM, Chew K, Benz C, Smith HS: Tumor labeling indices of primary breast cancers and their regional lymph node metastases. Cancer 71: 3914-3919, 1993
17. 17. Going JJ, Stanton PD, Cooke TG: Influences on measurement of cellular proliferation by histology and flow cytometry in mammary carcinomas labeled in vivo with bromodeoxyuridine. Am J Clin Pathol 100: 218-222, 1993
18. 18. Stanton PD, Cooke TG, Forster G, Smith D, Going JJ: Cell kinetics in vivo of human breast cancer. Br J Surg 83: 98-102, 1996
19. 19. Hoshino T, Prados M, Wilson CB, Cho KG, Lee KS, Davis RL: Prognostic implications of the bromodeoxyuridine labeling index of human gliomas. J Neurosurg 71: 335-341, 1989
20. 20. Potten CS, Kellett M, Roberts SA, Rew DA, Wilson GD: Measurement of in vivo proliferation in human colorectal mucosa using bromodeoxyuridine. Gut 33: 71-78, 1992
21. 21. Erba E, Giordano M, Danova M, Mazzini G, Ubezio P, Torn V, Mangioni C, Landoni F, Bolis P, Tenti P: Cell kinetics of human ovarian cancer with in vivo administration of bromodeoxyuridine. Ann Oncol 5: 627-634, 1994
22. 22. Wilson GD, Dische S, Saunders MI: Studies with bromodeoxyuridine in head and neck cancer and accelerated radiotherapy. Radiother Oncol 36: 189-197, 1995
23. 23. Tinnemans MMFJ, Lenders MHJH, Ten Velde GPM, Wagenaar SS, Blijham GH, Ramaekers FC, Schutte B: Evauation of proliferation parameters in in vivo bromodeoxyuridine labeled lung cancers. Virchows Arch 427: 295-301, 1995
24. 24. Nemoto R, Hattori K, Uchida K, Shimazui T, Koiso K, Harada M: Estimation of growth fraction in situ in human bladder cancer with bromodeoxyuridine labeling. Br J Urol 65: 27-31, 1990
25. 25. Brown DC, Gatter KC: Monoclonal antibody Ki-67: its use in histopathology. Histopathol 17: 489-503, 1990
26. 26. Zolzer F, Speer A, Pelzer T, Streffer C, Evidence for quiescent S- and G2-phase cells in human colorectal carcinomas: a flow cytometric study with the Ki-67 antibody. Cell Proliferation 28: 313-327, 1995
27. 27. van Dierendonk, JH, Keijzer, R, van de Velde CJH, Cornelisse CJ: Nuclear distribution of the Ki-67 antigen during the cell cycle: Comparison with growth fraction in human breast cancer cells. Canc Res 49: 2999-3006, 1989
28. 28. Gasparini G, Boracchi P, Verderio P, Bevilacqua P: Cell kinetics in human breast cancer: comparison between the prognostic value of the cytofluorimetric S-phase fraction and that of the antibodies to Ki-67 and PCNA antigens detected by immunocytochemistry. Int J Cancer 57: 822-829, 1994
29. 29. Goodson WH III, Moore DH II, Ljung BM, Chew K, Florendo C, Mayall B, Smith HS, Waldman FM: The functional relationship between in vivo bromodeoxyuridine labeling index and Ki-67 proliferation index in human breast cancer. Breast Cancer Res Treat 49: 155-164, 1998
30. 30. Verhoeven D, Bourgeois N, Derde MP, Kaufman L, Buyssens N: Comparison of cell growth in different parts of breast cancers. Histopathology 17: 505-509, 1990
31. 31. Eugene S Edgington: Randomization Tests, 2nd edition, Marcel Dekker, New York, 1987
32. 32. Pierga YJ, Leroyer A, Viehl P, Mosseri V, Chevillard S, Magdelenat H: Long term prognostic value of growth fraction determination by Ki-67 immunostaining in primary operable breast cancer. Breast Cancer Res Treat 37: 57-64, 1996
33. 33. Meyer JS, Province MA: S-phase fraction and nuclear size in long-term prognosis of patients with breast cancer. Cancer 74: 2287-2299, 1994
34. 34. Gaglia P, Bernardi A, Venesio T, Caldarola B, Lauro D, Cappa AP, Calderini P, Liscia DS: Cell proliferation of breast cancer evaluated by anti-BrdU and anti-Ki-67 antibodies: Its prognostic value on short-term recurrences. Eur J Cancer 1993; 29A: 1509-1513, 1993
35. 35. Thor AD, Liu S, Moore HD II, Edgerton SM: Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-I assays to quantitate proliferation in breast cancer. J Clin Oncol 17: 470-477, 1999
36. 36. Hutchins L, Green S, Ravdin P, Lew D, Martino M, Abeloff A, Lyss A, Henderson IC, Allred C, Dakhil S, Pierce I, Goodwin W, Caton J, Rivkin S, Chapman R, Osborne K: CMF versus CAP with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low risk node-negative patients: first results of Intergroup Trial INT 0102. Proc Am Soc Clin Oncol 17: Ia, 1998
37. 37. Railo M, Lundin J, Haglund C, von Smitten K, von Boguslawsky K, Nordling S. Ki-67, p53, Er-receptors, ploidy, and S-phase as prognostic factors in T-1 node negative breast cancer. Acta Oncolog 36: 369-374, 1997
38. 38. Hedley DW, Clark GM, Cornelisse CJ, Killander D, Kute T, Merkel D: Concensus review of the clinical utility of DNA cytometry in carcinoma of the breast. Breast Cancer Res Treat 28: 55-59, 1993
39. 39. Hatschek T, Grontoft O, Fagerberg G, Stal O, Sullivan S, Carstensen J, Nordenskjold B: Cytometric and histopathologic features of tumors detected in a randomized mammography screening program: correlation and relative prognostic influence. Breast Cancer Treat Res 15: 149-160, 1990
40. 40. Lipponen P, Papinaho S, Eskelinen M, Klemi PJ, Aaltomaa S, Kosma VM, Marin S, Syrianen K: DNA ploidy, S-phase fraction and mitotic indices as prognostic predictors of female breast cancer. Anticanc Res 12: 1533-1538, 1992
41. 41. Giuliano A, Jones, RC, Brennan M, Statman R: Sentinel lymphadenectomy in breast cancer. J. Clin Oncol 15: 2345-2350, 1997
42. 42. Guenther JM, Krishnamoorthy M, Tan LR: Sentinel lymphadenectomy for breast cancer in a community managed care setting. Cancer J Sci Am 3: 336-340, 1997
43. 43. Veronesi U, Paganelli G, Galimberti V, Viale G, Zurrida S, Bedoni M, Costa A, de Cicco C, Geraghty JG, Luini A, Sacchini V, Veronesi P: Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 349: 1864-1867, 1997
44. 44. Peduzzi P, Concato J, Feinstein AR, Holford TR: Importance of events per independent variable in proportional hazards regression analysis II. Accuracy and precision of regression estimates. J Clin Epidemiol 48: 1503-1510, 1995